Total Payments
$41,476
2024 Payments
$4,418
Companies
88
Transactions
1,100
Medicare Patients
5,664
Medicare Billing
$1.9M
Payment Breakdown by Category
Food & Beverage$20,024 (48.3%)
Other$16,789 (40.5%)
Consulting$4,114 (9.9%)
Education$549.40 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $20,024 | 1,070 | 48.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,300 | 11 | 32.1% |
| Consulting Fee | $4,114 | 2 | 9.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,070 | 1 | 5.0% |
| Honoraria | $920.00 | 1 | 2.2% |
| Education | $549.40 | 10 | 1.3% |
| Long term medical supply or device loan | $498.50 | 5 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Global Blood Therapeutics, Inc. | $11,791 | 14 | $0 (2022) |
| Merck Sharp & Dohme LLC | $6,249 | 95 | $0 (2024) |
| GENZYME CORPORATION | $2,656 | 28 | $0 (2024) |
| Clovis Oncology, Inc. | $2,171 | 6 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,806 | 87 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,458 | 97 | $0 (2024) |
| PFIZER INC. | $1,314 | 95 | $0 (2024) |
| Janssen Biotech, Inc. | $1,039 | 57 | $0 (2024) |
| Amgen Inc. | $1,023 | 49 | $0 (2023) |
| Celgene Corporation | $933.79 | 56 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,418 | 196 | Merck Sharp & Dohme LLC ($430.41) |
| 2023 | $7,673 | 221 | Merck Sharp & Dohme LLC ($2,565) |
| 2022 | $10,510 | 266 | Global Blood Therapeutics, Inc. ($3,041) |
| 2021 | $6,111 | 35 | Global Blood Therapeutics, Inc. ($5,520) |
| 2020 | $5,517 | 18 | Global Blood Therapeutics, Inc. ($3,230) |
| 2019 | $1,381 | 103 | Merck Sharp & Dohme Corporation ($235.14) |
| 2018 | $1,829 | 134 | Merck Sharp & Dohme Corporation ($227.42) |
| 2017 | $4,036 | 127 | GENZYME CORPORATION ($2,142) |
All Payment Transactions
1,100 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $7.49 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.17 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $8.67 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $9.65 | General |
| Category: Oncology | ||||||
| 12/10/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $20.98 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.10 | General |
| Category: Hematology | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $32.61 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $25.07 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Oncology | ||||||
| 11/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Oncology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $26.95 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/05/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.74 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/31/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $26.95 | General |
| 10/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 1,302 | 35,253 | $3.3M | $855,127 |
| 2022 | 26 | 1,021 | 21,358 | $1.1M | $267,916 |
| 2021 | 37 | 1,775 | 27,895 | $2.3M | $475,746 |
| 2020 | 37 | 1,566 | 29,484 | $1.9M | $342,729 |
Total Patients
5,664
Total Services
113,990
Medicare Billing
$1.9M
Procedure Codes
133
All Medicare Procedures & Services
133 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 10,800 | $1.7M | $466,340 | 27.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 37 | 10,980 | $702,333 | $199,491 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 136 | 441 | $171,726 | $40,396 | 23.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 36 | 286 | $165,772 | $36,821 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 186 | 350 | $96,734 | $21,449 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 131 | $71,938 | $17,677 | 24.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 48 | 159 | $66,603 | $15,687 | 23.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 2,000 | $50,002 | $11,937 | 23.9% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 36 | 100 | $21,000 | $7,125 | 33.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $26,247 | $5,792 | 22.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 235 | 728 | $21,112 | $5,518 | 26.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 45 | 170 | $17,342 | $3,680 | 21.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 34 | 59 | $12,262 | $2,889 | 23.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 12 | 6,630 | $26,520 | $2,828 | 10.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 72 | 273 | $17,791 | $2,827 | 15.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 39 | 101 | $13,265 | $2,341 | 17.6% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 13 | 25 | $8,143 | $1,592 | 19.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $6,123 | $1,553 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $7,084 | $1,540 | 21.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 11 | 32 | $5,646 | $1,311 | 23.2% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 51 | $5,340 | $1,248 | 23.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 16 | 17 | $4,539 | $1,183 | 26.1% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 24 | $4,320 | $1,082 | 25.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 11 | 15 | $3,045 | $738.28 | 24.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 23 | 59 | $3,628 | $698.55 | 19.3% |
About Dr. Amber Flaherty, M.D
Dr. Amber Flaherty, M.D is a Medical Oncology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2011. The National Provider Identifier (NPI) number assigned to this provider is 1093008336.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amber Flaherty, M.D has received a total of $41,476 in payments from pharmaceutical and medical device companies, with $4,418 received in 2024. These payments were reported across 1,100 transactions from 88 companies. The most common payment nature is "Food and Beverage" ($20,024).
As a Medicare-enrolled provider, Flaherty has provided services to 5,664 Medicare beneficiaries, totaling 113,990 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 133 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Phoenix, AZ
- Active Since 05/19/2011
- Last Updated 09/11/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1093008336
Products in Payments
- OXBRYTA (Drug) $8,905
- KEYTRUDA (Biological) $3,929
- JEVTANA (Drug) $2,435
- Rubraca (Drug) $2,147
- OPDIVO (Biological) $1,155
- Lenvima (Drug) $527.62
- CABOMETYX (Drug) $510.21
- REBLOZYL (Biological) $443.88
- KISQALI (Drug) $431.74
- Enhertu (Drug) $418.60
- XTANDI (Drug) $370.62
- IBRANCE (Drug) $356.48
- IMBRUVICA (Drug) $297.31
- Pomalyst (Drug) $285.15
- JAKAFI (Drug) $256.08
- ERLEADA (Drug) $255.14
- Alecensa (Biological) $244.61
- VERZENIO (Drug) $229.81
- Nplate (Biological) $222.59
- AYVAKIT (Drug) $212.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Phoenix
Dr. Jason Salganick, Md, MD
Medical Oncology — Payments: $1.9M
Medical Oncology $1.9M
Mazen Khattab, Md, MD
Medical Oncology — Payments: $226,385
Medical Oncology $226,385
Panayiotis Savvides, Md, MD
Medical Oncology — Payments: $217,105
Medical Oncology $217,105
Tania Cortas, Md, MD
Medical Oncology — Payments: $36,718
Medical Oncology $36,718
Waqas Arslan, M.d, M.D
Medical Oncology — Payments: $34,523
Medical Oncology $34,523
Dr. Amir Azadi, M.d, M.D
Medical Oncology — Payments: $23,762
Medical Oncology $23,762